David Southwell
Director/Board Member at ROCKET PHARMACEUTICALS, INC.
Net worth: 4 M $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Stephanie Sullivan | F | 51 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | - |
James Hunt | M | 72 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 7 years |
Gaurav D. Shah | M | 49 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | 9 years |
Nancy Hawthorne | F | 72 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 15 years |
Gavin MacBeath | M | 54 | 6 years | |
Matthew Klein | M | 52 | 5 years | |
Chris Flynn | M | 50 | 17 years | |
David Keith Downes | M | 84 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 10 years |
John Anthony Sommers | M | 85 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 7 years |
Keith Hughes | M | 77 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 8 years |
Kinnari Patel | M | 45 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | 8 years |
Carsten Boess | M | 57 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 8 years |
John Militello | M | 50 | 6 years | |
Neil Almstead | M | 57 | 24 years | |
Sabrina Rusnak-Carlson | F | 45 | 9 years | |
Christine Utter | F | 46 | 14 years | |
Allan Jacobson | M | 78 | 26 years | |
Stephen Biggar | M | 53 | 3 years | |
Michael Schmertzler | M | 72 | 23 years | |
Richard Simon | M | - |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | - |
Cynthia Smith | F | 55 | 5 years | |
Leiden Dworak | M | - | 2 years | |
Margareta Elisabeth Björk | M | 62 | 4 years | |
Mark White | M | 57 | 1 years | |
Alex Simon | M | - |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | - |
Katina Dorton | F | 66 | 3 years | |
Gabriela Gruia | M | 67 | 3 years | |
R. Woods | M | 56 | 1 years | |
Mary Smith | F | 61 | 3 years | |
Ellen Welch | M | - | - | |
Martin Wilson | M | 47 | 3 years | |
Gayatri R. Rao | M | - | 6 years | |
Stephanie Okey | F | 64 | 6 years | |
Jonathan Schwartz | M | 60 | 8 years | |
Zoran Zdraveski | M | 54 | 3 years | |
Chester Koczynski | M | - |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 years |
James D. Kern | M | 57 | 10 years | |
Fady Malik | M | 60 | 2 years | |
Frank Thomas | M | 54 | 7 years | |
Deborah McAneny | F | 65 | 9 years | |
John Pottage | M | 71 | 6 years | |
Alexandra Glucksmann | M | 65 |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | 1 years |
Mark Boulding | M | 63 | 22 years | |
Emma Reeve | F | 63 | 6 years | |
Naveen Yalamanchi | M | 47 | 6 years | |
Gotham Makker | M | 52 | 6 years | |
Jerome Zeldis | M | 74 | 12 years | |
Martin Rexroad | M | - | 11 years | |
Dan Troy | M | 64 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 years |
Glenn Steele | M | 79 | 9 years | |
Alethia Young | F | 45 | 2 years | |
Pedro Granadillo | M | 77 | 6 years | |
Melodie R. Domurad | M | 66 |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | 16 years |
Eric Pauwels | M | 63 | 9 years | |
Richard J. Faleschini | M | 77 |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | 20 years |
John H. MacKinnon | M | 83 |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | 21 years |
Leah Amir | F | - |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | 26 years |
William Bell | M | 67 | 1 years | |
Adrian Rawcliffe | M | 52 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 years |
Kevin Giordano | M | - | 3 years | |
Marla Weetall | M | - | 22 years | |
Christopher Trotta | M | - | - | |
Peter Chandler Sutcliffe | M | 74 |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | 22 years |
Rod Wong | M | 47 | 6 years | |
Mayo Pujols | M | 55 | 2 years | |
Raj Prabhakar | M | 50 | 7 years | |
David Redfern | M | 57 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 years |
Pierre Gravier | M | 39 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Terrence Olson | M | 56 | 12 years | |
Timothy Barberich | M | 76 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 7 years |
Christoph Westphal | M | 56 | 3 years | |
Dale Ritter | M | 73 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
Brian Silver | M | 55 | 2 years | |
Lea Hachigian | M | - | 3 years | |
Antony Loebel | M | 64 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | - |
Brian Batchelder | M | - | - | |
Adrian Adams | M | 73 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 4 years |
Sam Tillinghast | M | 61 | - | |
Michael Loberg | M | 76 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 8 years |
Ittai Harel | M | 56 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 11 years |
William McVicar | M | 66 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA.
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 18 years |
Marcio Souza | M | 45 | 6 years | |
Lisa McGrath | F | - |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | - |
Mark Iwicki | M | 57 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 5 years |
Claudine Prowse | M | - |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 3 years |
Stuart Peltz | M | 64 | 25 years | |
Joel D. Sendek | M | 57 | 2 years | |
Argeris Karabelas | M | 71 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 years |
Michael Bell | M | 68 |
inVentiv Health, Inc.
inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | 2 years |
Jim O'Shea | M | 74 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 8 years |
H. Watkins | M | 71 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 8 years |
Deirdre Connelly | F | 63 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 3 years |
Mayur Kasetty | M | - | 4 years | |
Jonae R. Barnes | F | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | 13 years |
Maxine Gowen | M | 66 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 4 years |
Roger Norman Freeman | M | 82 |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 16 years |
Devang Vallabhdas Kantesaria | M | 51 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 years |
Henry E. Lentz | M | 79 |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 17 years |
Todd Bazemore | M | 53 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | - |
Barry A. Labinger | M | 60 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Southwell
- Personal Network